Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomide.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01458730

Enrollment

Registered

2011-10-25

Start date

2007-05-31

Completion date

2022-08-31

Last updated

2022-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Nervous System Lymphoma

Keywords

PCNSL, Immunochemotherapy, Intraspinal Depocyt, Maintenance temozolomide

Brief summary

The purpose of the study is to test the efficacy and tolerability of a multiagent chemotherapy treatment regimen without radiotherapy in patients with newly diagnosed lymphoma in the brain.

Detailed description

The objective of the study is 1. To investigate the efficacy and safety of a high-dose methotrexate-based induction polychemotherapy regimen combined with Rituximab and intraspinal DepoCyte followed by temozolomide maintenance treatment in newly diagnosed primary central nervous system lymphoma 2. To assess the long term outcome concerning neurotoxicity

Interventions

DRUGImmunochemotherapy

Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Pathologically verified primary central nervous system lymphoma No prior PCNSL treatment. * Patients treated with steroids alone are eligible * No signs of lymphoma outside the CNS * ECOG performance status 0-4 * Age \> 17 and \< 76 years * Written informed consent from the patient or guardian

Exclusion criteria

* Cardiac failure \> 3 * Pregnancy or lactation. Women of childbearing potential are requested to use an effective method of contraception to avoid pregnancy for a period from entry to the study and at least 3 months after the last study medication * Previous malignancy unless disease free for at least five years * Active infection. * Regarding tuberculosis, patients at risk should be tested for latent TB according local practice at each treating centre. * Positive HIV status * Organ transplantation * Serious psychiatric illness * Prior radiotherapy to the brain * Concomitant anti-inflammatory medication that cannot be discontinued * Creatinine clearance \< 60 ml/minute calculated by Cockcroft and Gault formula * Peripheral blood count with granulocytes \<1.5 x 109L or platelets \< 100 x 109L * Serum bilirubin \>1.5 times or ASAT and alkaline phosphatase \>2 times upper limits of normal. * Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any component of Rituximab excludes patients from Rituximab treatment, but not from the remaining part of the study

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
response rate	at completion of therapy
neurotoxicity	1-10 years after completion of therapy

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026